Changes to homoeopathic remedy licensing announced by MHRA
New rules, to be introduced by the Medicines and Healthcare products Regulatory Agency, will create a more level market in homoeopathic remedies.
The rules mean that manufacturers of newer products will be able to tell
prospective purchasers what conditions their products are intended to
be used for, in line with claims that can be made for products that were
on the market before 1971.
Manufacturers will be allowed to claim that products provide relief from
the symptoms of a range of conditions, from chilblains to psoriasis.
Makers of pre-1971 products will be able to re-register them under the
new scheme and update their claims. No evidence of efficacy will be required.
MHRA chief executive Kent Woods said: “This is a significant step
forward in the way homoeopathic medicines are regulated. Products authorised
under the national rules scheme will have to comply with recognised
standards of quality safety and patient information.”
Although legislation
for the new scheme came into effect on 1 September,
an MHRA spokesman explained that details of how the scheme will work
are still being written. |
The
Pharmaceutical Journal
Acrobat
Reader